The absence of a protein that activates the body's antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition that is treatable with an FDA-approved class of drugs known as TNF (tumor necrosis factor) inhibitors, a global research team led by Mount Sinai has found.
The absence of a protein that activates the body’s antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition called TBK1, which is treatable with an existing FDA-approved drug.
Scientists found that a rare rheumatoid-like autoinflammatory condition that is treatable with a class of drugs known as TNF (tumor necrosis factor) inhibitors.
Mount Sinai Recruits Internationally Recognized Cardiovascular Immunology Researcher miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Early-stage lung cancer coopts macrophages to help tumors invade lung tissues
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in
Nature in June.
The researchers found that early-stage lung cancer tumors coopt the immune cells, known as tissue-resident macrophages, to help invade lung tissue. They also mapped out the process, or program, of how the macrophages allows a tumor to hurt the tissues the macrophage normally repairs. This process allows the tumor to hide from the immune system and proliferate into later, deadly stages of cancer.